RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
Arteriovenous Malformation of Central Nervous System
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Cohort|
|Target Follow-Up Duration:||20 Years|
|Official Title:||Multi-Institution Registry of SRS/SBRT Procedures|
- Overall survival [ Time Frame: Up to 5 years ]
- Local recurrence [ Time Frame: One to Five years ]
- Treatment toxicity [ Time Frame: Immediate -5 years ]Complications of treatment. These complications are organ specific depending on which organ is being treated. For example, if the prostate is being treated,there may be rectal and urinary complications. If the brain is being treated, there may be headaches or nausea. The Radiation Therapy Oncology Group (RTOG) scale used for defining and measuring complications of radiotherapy is incorporated into the Registry database.
|Study Start Date:||March 2012|
|Estimated Study Completion Date:||December 2025|
|Estimated Primary Completion Date:||December 2020 (Final data collection date for primary outcome measure)|
Patients being treated by SRS/SBRT
Patients with a condition being considered for treatment by SRS/SBRT
Intervention varies by condition being treated.
The Registry is designed to help SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) users to understand utilization of and key treatment outcomes for these treatment approaches. Some of the objectives include:
Allow participants to record information about usage of SRS/SBRT in everyday practice, including patient characteristics and disease information, treatment plans and outcomes Provide participants with ready access to data for publication of their own experience and as a tool for establishing collaborations with other participating sites Facilitate quality improvement efforts for individual treatment providers Understand the effectiveness of different treatment plans for different types of lesions, diseases and treatments
The Registry tracks select outcomes for each condition treated by SRS/SBRT (for example, PSA for prostate cancer); the Registry also provides individual participants the ability to add additional outcomes for each and any condition of specific interest to their institutions.
The Registry is hosted by Advertek, Inc who is an independent vendor of electronic registries; they are responsible for HIPAA compliance, including all security mechanisms.
Patients will be enrolled prospectively. Some retrospective patient data is likely to be included in order to capture both short and longer term outcomes data.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01885299
Show 25 Study Locations
|Study Director:||Clinton Medbery, MD||The Radiosurgery Society|